8 recruiting, 6 not yet recruiting. 5 Phase 1, 3 Not applicable, 2 Early Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Not yet recruiting 3, Recruiting 2 |
| Not applicable | 3 | Not yet recruiting 2, Recruiting 1 |
| Early Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow Systemic Lupus Erthematosus (SLE): new trials by email Literature Review of Systemic Lupus Erthematosus (SLE) trials Research Report on Systemic Lupus Erthematosus (SLE)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Team-based Implementation of Hypertension Management in Childhood Lupus Health Navigator Engagement, Team Charter with Performance Monitoring, Pre-visit worksheet - Systemic Lupus Erthematosus (SLE) | Not applicable | Not yet recruiting | Boston Children's Hospital | 1200 | 2027-04-01 | 2026-08-28 |
| A Basket Study of CTA313 in Participants With Active Autoimmune Diseases CTA313 UCAR T Cell Infusion - Systemic Lupus Erthematosus (SLE), Progressive Multiple Sclerosis (PMS) | Phase 1 | Not yet recruiting | Imviva Bio | 81 | 2026-12-01 | 2026-08-24 |
| BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease LMY-922 - Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Luminary Therapeutics | 94 | 2026-10-01 | 2026-07-28 |
| Effect of Anti-inflammatory Diet in Systemic Lupus Erythematous anti-inflammatory diet - Systemic Lupus Erthematosus (SLE) | Not applicable | Recruiting | University of California, San Diego | 36 | 2026-07-01 | 2026-07-20 |
| Non Invasive Assessment of Subclinical Atherosclerosis and Cardiovascular Risk Using TYG Index in Lupus Nephritis Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not yet recruiting | Assiut University | 156 | 2026-07-01 | 2026-07-22 | |
| A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases MTM-H-001 Injection - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Not applicable | Not yet recruiting | Beijing GoBroad Hospital | 75 | 2026-06-01 | 2026-05-18 |
| 2-HOBA in Systemic Lupus Erythematosus 2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo - Systemic Lupus Erthematosus (SLE) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 42 | 2026-05-15 | 2026-05-22 |
| CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease QT-219CX - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-05-08 | 2026-05-14 |
| Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Early Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2026-04-01 | 2026-04-02 |
| A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) HB2198 - Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN) | Phase 1 | Recruiting | Hinge Bio | 30 | 2026-03-23 | 2026-03-25 |
| KN5501 Cell Injection for Refractory SLE(CLEAR) KN5501 cell injection - Systemic Lupus Erthematosus (SLE) | Phase 1 | Not yet recruiting | Ruitherapeutics Co., LTD | 36 | 2026-01-01 | 2026-01-22 |
| CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease UCAR T-cell - Autoimmune Diseases, Systemic Lupus Erthematosus (SLE) | Phase 1 | Recruiting | The Children's Hospital of Zhejiang University School of Medicine | 15 | 2025-12-01 | 2026-02-03 |
| The RheumSafer Study: Improving Medication Appropriateness in People With Rheumatic Conditions MedSafer deprescribing opportunity reports, EMPOWER brochures - Rheumatic Diseases, Inflammatory Arthritis | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 100 | 2025-10-29 | 2026-05-01 | |
| Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy Ex Vivo Assay - Rheumatic Diseases, Rheumatoid Arthritis (RA) | Recruiting | University of Bonn | 120 | 2025-04-01 | 2025-09-02 |
Scleroderma, Systemic (5) · Lupus Nephritis (4) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Arthritis, Rheumatoid (3) · Autoimmune Diseases (3) · Glomerulonephritis, IGA (3) · Nephrotic Syndrome (3) · Rheumatic Diseases (2) · Arthritis (1) · Arthritis, Gouty (1) · Arthritis, Psoriatic (1) · Autoimmune Diseases of the Nervous System (1) · Connective Tissue Diseases (1) · Dermatomyositis (1) · Giant Cell Arteritis (1)
Immune System Diseases (10) · Skin and Connective Tissue Diseases (10) · Connective Tissue Diseases (9) · Autoimmune Diseases (7) · Female Urogenital Diseases (7) · Female Urogenital Diseases and Pregnancy Complications (7) · Glomerulonephritis (7) · Kidney Diseases (7) · Male Urogenital Diseases (7) · Nephritis (7) · Urogenital Diseases (7) · Urologic Diseases (7) · Cardiovascular Diseases (5) · Skin Diseases (5) · Vascular Diseases (5)
The Children's Hospital of Zhejiang University School of Medicine (3) · Assiut University (1) · Beijing GoBroad Hospital (1) · Boston Children's Hospital (1) · Hinge Bio (1) · Imviva Bio (1) · Luminary Therapeutics (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Ruitherapeutics Co., LTD (1) · University of Bonn (1) · University of California, San Diego (1) · Vanderbilt University Medical Center (1)
China (5) · United States (3) · Australia (1) · Canada (1) · Egypt (1) · Germany (1)
Arielle Mendel, MD MSc (1) · Jing Pan, Ph.D (1) · Mengtao Li (1) · Michelle J Ormseth, MD, MSCI (1) · Monica Guma, MD, PhD (1)
P01HL174442 (1)